• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

    Simply Wall St·08/03/2026 22:28:25
    Listen to the news
    • In the second quarter of 2026, Veracyte, Inc. reported revenue of US$150.32 million versus US$130.16 million a year earlier, with net income of US$25.49 million compared with a net loss of US$0.98 million, and also raised full-year 2026 revenue guidance to a range of US$590 million to US$596 million.
    • The company attributed its stronger results and improved outlook in part to the launches of its Prosigna breast cancer test and TrueMRD bladder cancer recurrence-monitoring test, which further extend its presence across the cancer diagnostics continuum.
    • We’ll now examine how Veracyte’s upgraded 2026 revenue guidance, backed by new cancer tests, affects its broader investment narrative.

    Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

    Veracyte Investment Narrative Recap

    To own Veracyte, you need to believe its cancer diagnostics portfolio can broaden beyond Decipher and Afirma while maintaining healthy profitability. The upgraded 2026 revenue guidance, supported by strong Q2 results, modestly reinforces that near term catalyst, but also highlights the main risk: new tests like Prosigna and TrueMRD still depend on sustained clinical adoption and payer coverage to truly reduce Veracyte’s reliance on its legacy franchises.

    The most relevant recent announcement here is Veracyte’s decision to raise its 2026 total revenue guidance to US$590 million to US$596 million, up from US$582 million to US$592 million. This increase, coming alongside meaningful year over year revenue and earnings improvement, ties directly into the catalyst of pipeline execution and suggests that early traction from new tests is beginning to contribute to the broader growth story, even as reimbursement and pricing pressures remain important watchpoints.

    Yet beneath the upgraded guidance, investors should be aware that concentrated reliance on a few flagship tests still leaves Veracyte exposed if...

    Read the full narrative on Veracyte (it's free!)

    Veracyte's narrative projects $744.2 million revenue and $115.6 million earnings by 2029. This requires 11.2% yearly revenue growth and about $27.6 million earnings increase from $88.0 million today.

    Uncover how Veracyte's forecasts yield a $56.55 fair value, a 22% upside to its current price.

    Exploring Other Perspectives

    VCYT 1-Year Stock Price Chart
    VCYT 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming Veracyte could lift revenue to about US$767.3 million and earnings to roughly US$135.6 million by 2029, which is far more bullish than the baseline view and may look different now that Q2 results and the guidance raise have arrived.

    Explore 3 other fair value estimates on Veracyte - why the stock might be worth just $56.55!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.